Log in

NASDAQ:PRPOPrecipio Competitors & Alternatives

$3.16
-0.30 (-8.67 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.00
Now: $3.16
$3.44
50-Day Range
$1.13
MA: $1.72
$7.00
52-Week Range
$0.55
Now: $3.16
$8.00
Volume2.13 million shs
Average Volume9.22 million shs
Market Capitalization$46.20 million
P/E RatioN/A
Dividend YieldN/A
Beta3.11

Competitors

Precipio (NASDAQ:PRPO) Vs. ILMN, A, MTD, BIO.B, BIO, and PKI

Should you be buying PRPO stock or one of its competitors? Companies in the industry of "analytical instruments" are considered alternatives and competitors to Precipio, including Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), and PerkinElmer (PKI).

Precipio (NASDAQ:PRPO) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Institutional & Insider Ownership

2.6% of Precipio shares are owned by institutional investors. Comparatively, 89.9% of Illumina shares are owned by institutional investors. 9.7% of Precipio shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Precipio and Illumina's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precipio$3.13 million14.76$-13,240,000.00N/AN/A
Illumina$3.54 billion14.76$1.00 billion$6.5754.13

Illumina has higher revenue and earnings than Precipio.

Profitability

This table compares Precipio and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precipio-407.60%-109.58%-71.10%
Illumina20.67%19.14%12.09%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Precipio and Illumina, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precipio00103.00
Illumina241002.50

Precipio currently has a consensus target price of $2.00, indicating a potential downside of 36.71%. Illumina has a consensus target price of $341.3125, indicating a potential downside of 4.03%. Given Illumina's higher probable upside, analysts plainly believe Illumina is more favorable than Precipio.

Volatility and Risk

Precipio has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500. Comparatively, Illumina has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Summary

Illumina beats Precipio on 8 of the 12 factors compared between the two stocks.

Precipio (NASDAQ:PRPO) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Institutional & Insider Ownership

2.6% of Precipio shares are owned by institutional investors. 9.7% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Precipio and Agilent Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precipio$3.13 million14.76$-13,240,000.00N/AN/A
Agilent Technologies$5.16 billion5.85$1.07 billion$3.1131.44

Agilent Technologies has higher revenue and earnings than Precipio.

Profitability

This table compares Precipio and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precipio-407.60%-109.58%-71.10%
Agilent Technologies13.04%20.76%10.72%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Precipio and Agilent Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precipio00103.00
Agilent Technologies012802.40

Precipio currently has a consensus target price of $2.00, indicating a potential downside of 36.71%. Agilent Technologies has a consensus target price of $82.8235, indicating a potential downside of 15.30%. Given Agilent Technologies' higher probable upside, analysts plainly believe Agilent Technologies is more favorable than Precipio.

Volatility and Risk

Precipio has a beta of 3.11, suggesting that its share price is 211% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Summary

Agilent Technologies beats Precipio on 7 of the 12 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Precipio (NASDAQ:PRPO) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Mettler-Toledo International and Precipio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mettler-Toledo International18.61%138.77%20.40%
Precipio-407.60%-109.58%-71.10%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Mettler-Toledo International and Precipio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mettler-Toledo International27001.78
Precipio00103.00

Mettler-Toledo International presently has a consensus price target of $720.7778, indicating a potential downside of 23.66%. Precipio has a consensus price target of $2.00, indicating a potential downside of 36.71%. Given Mettler-Toledo International's higher probable upside, analysts plainly believe Mettler-Toledo International is more favorable than Precipio.

Institutional & Insider Ownership

94.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 2.6% of Precipio shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by insiders. Comparatively, 9.7% of Precipio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Mettler-Toledo International and Precipio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$3.01 billion7.50$561.11 million$22.7741.47
Precipio$3.13 million14.76$-13,240,000.00N/AN/A

Mettler-Toledo International has higher revenue and earnings than Precipio.

Volatility & Risk

Mettler-Toledo International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Precipio has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500.

Summary

Mettler-Toledo International beats Precipio on 7 of the 12 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO.B) and Precipio (NASDAQ:PRPO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Bio-Rad Laboratories and Precipio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories84.89%3.66%2.65%
Precipio-407.60%-109.58%-71.10%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Bio-Rad Laboratories and Precipio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories0000N/A
Precipio00103.00

Precipio has a consensus price target of $2.00, indicating a potential downside of 36.71%. Given Precipio's higher probable upside, analysts plainly believe Precipio is more favorable than Bio-Rad Laboratories.

Volatility & Risk

Bio-Rad Laboratories has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Precipio has a beta of 3.11, meaning that its share price is 211% more volatile than the S&P 500.

Institutional & Insider Ownership

0.1% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 2.6% of Precipio shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 9.7% of Precipio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Bio-Rad Laboratories and Precipio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion6.74$1.76 billionN/AN/A
Precipio$3.13 million14.76$-13,240,000.00N/AN/A

Bio-Rad Laboratories has higher revenue and earnings than Precipio.

Summary

Bio-Rad Laboratories beats Precipio on 6 of the 11 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and Precipio (NASDAQ:PRPO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Bio-Rad Laboratories and Precipio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Rad Laboratories84.89%3.66%2.65%
Precipio-407.60%-109.58%-71.10%

Analyst Recommendations

This is a summary of current recommendations for Bio-Rad Laboratories and Precipio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Rad Laboratories00313.25
Precipio00103.00

Bio-Rad Laboratories presently has a consensus price target of $511.25, indicating a potential downside of 2.46%. Precipio has a consensus price target of $2.00, indicating a potential downside of 36.71%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, equities research analysts clearly believe Bio-Rad Laboratories is more favorable than Precipio.

Risk and Volatility

Bio-Rad Laboratories has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Precipio has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500.

Institutional and Insider Ownership

62.9% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 2.6% of Precipio shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 9.7% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Bio-Rad Laboratories and Precipio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.31 billion6.73$1.76 billion$7.0674.24
Precipio$3.13 million14.76$-13,240,000.00N/AN/A

Bio-Rad Laboratories has higher revenue and earnings than Precipio.

Summary

Bio-Rad Laboratories beats Precipio on 11 of the 13 factors compared between the two stocks.

Precipio (NASDAQ:PRPO) and PerkinElmer (NYSE:PKI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

2.6% of Precipio shares are owned by institutional investors. Comparatively, 93.3% of PerkinElmer shares are owned by institutional investors. 9.7% of Precipio shares are owned by insiders. Comparatively, 0.6% of PerkinElmer shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Precipio and PerkinElmer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precipio-407.60%-109.58%-71.10%
PerkinElmer9.87%18.41%7.95%

Earnings and Valuation

This table compares Precipio and PerkinElmer's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precipio$3.13 million14.76$-13,240,000.00N/AN/A
PerkinElmer$2.88 billion4.61$227.56 million$4.1029.10

PerkinElmer has higher revenue and earnings than Precipio.

Analyst Ratings

This is a summary of recent ratings for Precipio and PerkinElmer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precipio00103.00
PerkinElmer08602.43

Precipio currently has a consensus target price of $2.00, indicating a potential downside of 36.71%. PerkinElmer has a consensus target price of $94.4286, indicating a potential downside of 20.87%. Given PerkinElmer's higher probable upside, analysts clearly believe PerkinElmer is more favorable than Precipio.

Volatility & Risk

Precipio has a beta of 3.11, indicating that its share price is 211% more volatile than the S&P 500. Comparatively, PerkinElmer has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500.

Summary

PerkinElmer beats Precipio on 8 of the 12 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Illumina logo
ILMN
Illumina
1.4$355.66-12.3%$52.28 billion$3.54 billion76.00Earnings Announcement
Analyst Downgrade
Insider Selling
High Trading Volume
Analyst Revision
Heavy News Reporting
Agilent Technologies logo
A
Agilent Technologies
1.5$97.78-0.3%$30.19 billion$5.16 billion45.06Increase in Short Interest
Mettler-Toledo International logo
MTD
Mettler-Toledo International
0.9$944.17-0.6%$22.57 billion$3.01 billion42.36Insider Selling
Decrease in Short Interest
Analyst Revision
BIO.B
Bio-Rad Laboratories
0.7$525.00-0.0%$15.58 billion$2.31 billion8.14
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$524.13-0.2%$15.56 billion$2.31 billion8.13Analyst Revision
PerkinElmer logo
PKI
PerkinElmer
1.7$119.33-0.2%$13.29 billion$2.88 billion45.37Decrease in Short Interest
Waters logo
WAT
Waters
1.2$212.34-0.8%$13.15 billion$2.41 billion26.44Decrease in Short Interest
AVTR
Avantor
1.5$21.67-2.4%$12.49 billion$6.04 billion94.22Increase in Short Interest
Analyst Revision
Bruker logo
BRKR
Bruker
2.2N/AN/A$6.81 billion$2.07 billion33.69Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
Coherent logo
COHR
Coherent
2.0$127.97-0.6%$3.10 billion$1.43 billion-7.32Earnings Announcement
Analyst Report
Analyst Revision
Quanterix logo
QTRX
Quanterix
1.3$33.12-5.5%$941.93 million$56.73 million-21.10Analyst Report
Insider Selling
High Trading Volume
Decrease in Short Interest
Analyst Revision
Heavy News Reporting
Accelerate Diagnostics logo
AXDX
Accelerate Diagnostics
2.1$15.50-5.2%$856.70 million$9.30 million-10.33Analyst Upgrade
Decrease in Short Interest
Heavy News Reporting
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.5$4.73-13.7%$729.89 million$90.89 million-14.33Earnings Announcement
Analyst Revision
Heavy News Reporting
Fluidigm logo
FLDM
Fluidigm
1.5$7.61-10.9%$538.07 million$117.24 million-9.76Earnings Announcement
Analyst Report
Heavy News Reporting
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.6$4.19-4.5%$160.81 million$116.18 million-19.05Earnings Announcement
High Trading Volume
Eyepoint Pharmaceuticals logo
EYPT
Eyepoint Pharmaceuticals
1.7$0.70-4.3%$87.65 million$20.36 million-1.52Earnings Announcement
Analyst Report
Decrease in Short Interest
Heavy News Reporting
BNGO
BioNano Genomics
1.3$0.86-7.0%$72.49 million$10.13 million-0.45Upcoming Earnings
Heavy News Reporting
HTG Molecular Diagnostics logo
HTGM
HTG Molecular Diagnostics
1.3$0.63-0.0%$42.58 million$19.20 million-1.55Upcoming Earnings
Analyst Report
Aethlon Medical logo
AEMD
Aethlon Medical
0.7$1.93-6.2%$23.30 million$650,000.00-0.42Upcoming Earnings
Decrease in Short Interest
Heavy News Reporting
This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.